QuidelOrtho Corp

QDELSEC EDGAR

In Vitro & In Vivo Diagnostic SubstancesCIK: 1906324

Concept	FY2025	FY2024	FY2023	FY2022
Revenues	$3.0B	$3.3B	$1.7B	$1.7B
Research and Development Expense	$245.0M	$187.9M	$95.7M	$84.3M
Selling, General and Administrative Expense	$763.2M	$621.0M	$239.6M	$180.7M
Operating Income (Loss)	$139.1M	$843.7M	$906.0M	$1.1B
Other Nonoperating Income (Expense)	-$20.6M	-$8.1M	$100.0K	-$1.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$29.1M	$735.9M	$900.3M	$1.0B
Income Tax Expense (Benefit)	-$19.0M	$187.2M	$196.1M	$230.0M
Net Income (Loss) Attributable to Parent	-$10.1M	$548.7M	$704.2M	$810.3M

Concept	FY2025	FY2024	FY2023	FY2022
Assets	$6.4B	$8.6B	$8.9B	$2.4B
Assets, Current	$1.2B	$1.3B	$1.6B	$1.4B
Cash and Cash Equivalents, at Carrying Value	$98.3M	$118.9M	$292.9M	$802.8M
Accounts Receivable, after Allowance for Credit Loss, Current	$282.4M	$303.3M	$453.9M	$378.0M
Inventory, Net	$533.7M	$577.8M	$524.1M	$198.8M
Liabilities	$3.4B	$3.6B	$3.9B	$501.0M
Liabilities, Current	$998.8M	$833.8M	$1.0B	$323.5M
Long-term Debt	$2.7B	$2.5B	$2.4B	$2.6B
Accounts Payable, Current

Concept	FY2025	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	$280.2M	$885.3M	$805.9M	$629.7M
Net Cash Provided by (Used in) Investing Activities	-$187.6M	-$1.6B	-$319.5M	-$63.3M
Net Cash Provided by (Used in) Financing Activities	-$265.8M	$252.0M	-$173.1M	-$130.3M
Payments to Acquire Property, Plant, and Equipment	$209.3M	$140.9M	$292.8M	$64.9M
Payments for Repurchase of Common Stock	$7.2M	$74.3M	$103.5M	$43.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)